Effective lovastatin therapy in elderly hypercholesterolemic patients - An antioxidative impact?

Archives of Gerontology and Geriatrics

Volumn 22, Issue 3, 1996, Pages 207-221

  Brosche, Thorolf ^a   Kral, Christiane ^a   Summa, Jörg Dieter ^a   Platt, Dieter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Apolipoprotein; Elderly; Fatty acids; Hypercholesterolemia; Lovastatin; Plasmalogen; Red cell membrane; Serum lipids; Vitamin E

Indexed keywords

ACETAL DERIVATIVE; ACYL COENZYME A DESATURASE; ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN; APOLIPOPROTEIN B; FATTY ACID; HYPOCHOLESTEROLEMIC AGENT; LINOLEIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHOSPHOLIPID; PLASMALOGEN;

ADULT; AGED; AORTA; ARTERIOSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL;

EID: 0029993003     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-4943(95)00694-X     Document Type: Article

References (51)

1. Aviram, M., Cogan, U., Dankner, G., Hochgraf, E. and Brook, G.J. (1990): LDL oxidation is inhibited by lovastatin. Abstract. Arteriosclerosis Dallas, 10, 793a.
2. Bagdade, J.D., Lane, J.T., Stone, N., Ritter, M.C. and Subbaiah, P.V. (1990): Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment. J. Lipid Res., 31, 1263-1269.
3. Behrens, W.A. and Madere, R. (1985): Transport of α- and γ-tocopherol in human plasma lipoproteins. Nutr. Res., 5, 167-174.
4. Black, D.M., Lucas, M.M., Versoza, S. and Stein, E.A. (1990): Effectiveness and safety of lovastatin and simvastatin in men and women over age 70. Arteriosclerosis Dallas, 10, 848a.
5. Blankenhorn, D.H., Azen, S.P., Kramsch, D.M., et al. (1993): Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann. Intern. Med., 119, 969-976.
6. Bradford, R.H., Shear, C.L. Chremos, A.N., et al. (1991): Expanded clinical evaluation of lovastatin (EXCEL) Study results I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med., 151, 43-49.
7. Bradford, R.H., Downton, M., Chremos, A.N., Langendörfer, A., Stinnett, S., Nash, D.T., Mantell, G. and Shear, C.L. (1993): Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann. Int. Med., 118, 850-855.
8. Bräutigam, C., Engelmann, B., Reiss, D., Reinhardt, U., Thiery, J., Richter, W.O. and Brosche, T. (1996): Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL-apheresis. Atherosclerosis, 119, 77-88.
9. Brosche, T., Platt, D. and Vostrowsky, O. (1985): Methyl enol ethers as artefacts in capillary gas Chromatographic profiles of aldehyde dimethyl acetals. J. Chromatogr., 345, 219-227.
10. Brosche, T., Heckers, H., Platt, D. and Summa, J.-D. (1986): The effect of different fat supplemented diets on the erythrocyte ghosts and plasma lipid composition of geriatric subjects. Arch. Gerontol. Geriatr., 5, 83-95.
11. Brosche, T. and Platt, D. (1987): Impaired glucose tolerance and plasma levels of vitamin E in geriatric subjects. Nutr. Rep. Int., 35, 575-582.
12. Brosche, T., Summa, J.-D. and Platt, D. (1989): Erythrocyte membrane changes associated with nutrition and aging - the role of plasmalogens. Arch. Gerontol. Geriatr., 9, 291-296.
13. Brown, B.G., Zhao, X.-Q., Sacco, D.E. and Albers, J.J. (1993): Atherosclerosis regression, plaque disruption and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu. Rev. Med., 44, 365-376.
14. Buddecke, E. and Andresen, G. (1959): Quantitative Bestimmung der Acetalphosphatide (Plasmalogene) in der Aorta des Menschen unter Berücksichtigung der Arteriosklerose. Hoppe-Seyler's Z. Physiol. Chem., 314, 38-45.
15. Clevidence, B.A. and Lehmann, J. (1989): α- and γ-tocopherol levels in lipoproteins fractionated by affinity chromatography. Lipids, 24, 137-140.
16. D'Agostino, R.B., Kannel, W.B., Stepanians, M.N. and D'Agostino, L.C. (1992a): Efficacy and tolerability of lovastatin in elderly hypercholesterolemic patients. Clin. Ther., 14, 68-76.
17. D'Agostino, R.B., Kannel, W.B., Stepanians, M.N. and D'Agostino, L.C. (1992b): Efficacy and tolerability of lovastatin in hypercholesterolemic women. Clin. Ther., 14, 390-395.
18. Davignon, J., Xhignesse, M., Mailloux, H., et al. (1993): Lovastatin 5-year safety and efficacy study. Arch. Int. Med., 153, 1079-1087.
19. Engelmann, B., Bräutigam, C. and Thiery, J. (1994): Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochim. Biophys. Res. Commun., 204, 1235-1242.
20. Esterbauer, H., Gebicki, J., Puhl, H. and Jürgens, G. (1992): The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med., 13, 341-390.
21. Georges, B., Blond, J.P., Maniongui, C. and Bézard, J. (1993): Effect of simvastatin on desaturase activities in liver from lean and obese Zucker rats. Lipids, 28, 63-65.
22. Grundy, S.M. and Vega, G.L. (1985): Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid Res., 26, 1464-1475.
23. Harman, D. (1956): Aging: a theory based on free radical and radiation chemistry. J. Gerontol., 11, 298-300.
24. Henwood, J.M. and Heel, R.C. (1988): Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs, 36, 429-454.
25. Hunninghake, D.B., Stein, E.A., Dujovne, C.A., Harris, W.S., Feldman, E.B., Miller, V.T., Tobert, J.A., Laskarzewski, P.M., Quiter, E., Held, J., Taylor, A.M., Hopper, S., Leonard, S.B. and Brewer, B.K. (1993): The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N. Engl. J. Med., 328, 1213-1219.
26. Illingworth, D.R. and Sexton, G.J. (1984): Hypercholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J. Clin. Invest., 74, 1972-1978.
27. Karlsson, J., Diamant, B., Theorell, H. and Folkers, K. (1993): Ubiquinone and α-tocopherol in plasma; means of translocation or depot. Clin. Investig., 71, S84-S91.
28. Kleinveld, H.A., Demacker, P.N.M., De Haan, A.F.J. and Stalenhoef, A.F.H. (1993): Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur. J. Clin. Invest., 23, 289-295.
29. Lehmann, J. (1978): Analysis of α-tocopherol in blood plasma and platelets by gas liquid chromatography. Lipids, 13, 616-618.
30. Lintott, C.J. and Scott, R.S. (1992): HMG-CoA reductase inhibitor use in the aged: a review of clinical experience. Drugs Aging, 2, 518-529.
31. Mangold, H.K. and Weber, N. (1987): Review: biosynthesis and biotransformation of ether lipids. Lipids, 22, 789-799.
32. Mercenne, F., Goudonnet, H., Mounie, J., Escousse, A. and Truchot, R.C. (1991): Effects of simvastatin, a lipoprotein-lowering drug, on the hepatic enzymes involved in drug metabolism in the Wistar rat. Xenobiotica, 21, 859-864.
33. Morrison, W.R. and Smith, L.M. (1964): Preparation of fatty acid methyl esters and dimethyl acetals from lipids with boron trifluoride-methanol. J. Lipid Res., 5, 600-608.
34. Nozaki, S., Vega, G.L., Haddox, R.J., Dolan, E.T. and Grundy, S.M. (1990): Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis, 84, 101-110.
35. Regnstrom, J., Nilsson, J., Tornvall, P., Landou, C. and Hamsten, A. (1992): Susceptibility of low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet, 339, 1183-1186.
36. Rimm, E.B., Stampfer, M.J., Ascherio, A., Giovannucci, E., Colditz, G.A., and Willett, W.C. (1993): Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med., 328, 1450-1456.
37. Scandinavian Simvastatin Survival Study Group (1994): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
38. Schectman, G., Hiatt, J. and Hartz, A. (1993): Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am. J. Cardiol., 71, 759-765.
39. Shear, C.L., Franklin, F.A., Stinnett, S., Hurley, D.P., Bradford, R.H., Chremos, A.N., Nash, D.T. and Langendorfer, A. (1992): Expanded clinical evaluation of lovastatin (EXCEL) study results: effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation, 85, 1293-1303.
40. Stampfer, M.J., Hennekens, C.H., Manson, J.E., Colditz, G.A., Rosner, B. and Willett, W.C. (1993): Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med., 328, 1444-1449.
41. Steinberg, D. and Witztum, J.L. (1990): Lipoproteins and atherogenesis: current concepts. J.Am. Med. Assoc., 264, 3047-3052.
42. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. and Witztum, J.L. (1989): Beyond cholesterol: modifications of low-density lipoproteins that increase its atherogenicity. N. Engl. J. Med., 320, 915-924.
43. Stocker, R. (1994): Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr. Opin. Lipidol., 5, 422-433.
44. Theodorsson-Norheim, E. (1987): Friedman and Quade tests: basic computer program to perform non-parametric two-way analysis of variance and multiple comparisons of ranks of several related samples. Comput. Biol. Med., 17, 85-99.
45. Thurnham, D.I., Davies, J.A., Crump, B.J., Situnayake, R.D. and Davies, M. (1986): The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann. Clin. Biochem., 23, 514-520.
46. Traber, M.G., Lane, J.C., Lagmay, N. and Kayden, H.J. (1992): Studies on the transfer of tocopherol between lipoproteins. Lipids, 27, 657-663.
47. Vanhanen, H. and Miettinen, T.A. (1992): Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia. Eur. J. Clin. Pharmacol., 42, 127-130.
48. Wissler, R.W. (1992): The pathobiologic basis of coronary atherosclerotic plaque regression. Cardiovasc. Risk Factors, 2, 218-223.
49. Yamamoto, A. (1991): Regression of atherosclerosis in humans by lowering serum cholesterol. Atherosclerosis, 89, 1-10.
50. Yavin, E. and Gatt, S. (1972): Oxygen-dependent cleveage of the vinyl-ether linkage of plasmalogens. Eur. J. Biochem., 25, 437-446.
51. Zoeller, R.A., Morand, O.H. and Raetz, C.R.H. (1988): A possible role for plasmalogens in protecting animal cells against photosensitized killing. J. Biol. Chem., 263, 11590-11596.